Educational guideComparison guide

Amanita Muscaria vs Psilocybin Mushrooms: why they should not be confused

Amanita muscaria and psilocybin mushrooms are frequently confused by the general public, but they have entirely different pharmacological profiles, different active compounds, and different risk contexts. This guide explains why confusing them can be dangerous — not as a guide to identification or use.

Educational context

This guide provides educational context only. It is not a use guide, medical advice, legal advice, dosing guidance or sourcing guidance.

Review status

needs-reviewneeds-review

Source and safety review are ongoing. How review status works

Background

Why the confusion matters

Amanita muscaria (fly agaric) and psilocybin-containing mushrooms are visually and culturally associated in ways that lead to frequent misidentification and mischaracterisation. They are not interchangeable. They do not contain the same compounds. Their effects, risks and safety profiles are fundamentally different. Understanding this distinction is important safety context.

This guide is educational context — not a mushroom identification guide. Wild foraging carries serious risk of poisoning from misidentification. The Amanita genus contains some of the world's most toxic mushrooms.

Pharmacology

Different compounds, different pharmacology

Psilocybin mushrooms contain psilocybin and psilocin, which primarily act on serotonin receptors. Amanita muscaria contains muscimol and ibotenic acid. Muscimol acts on GABA-B receptors, producing sedative and dissociative effects. Ibotenic acid is a neurotoxic compound. These are distinct mechanisms producing different effects and different risks. Ibotenic acid's neurotoxicity is a safety concern not present with psilocybin.

  • Psilocybin mushrooms: psilocybin and psilocin (serotonergic).
  • Amanita muscaria: muscimol and ibotenic acid (GABA-ergic and neurotoxic).
  • Different receptor systems, different effect profiles, different risk contexts.
  • Ibotenic acid is neurotoxic. No equivalent concern exists with psilocybin.

Reported effects

Effect profile differences

Psilocybin is associated with altered visual perception, emotional shifts and changes in the sense of time — effects attributed to serotonergic activity. Amanita muscaria is associated with dreamlike or delirious states, sedation, confusion and loss of coordination — not the visual and perceptual profile of psilocybin. Nausea and vomiting are commonly reported with Amanita muscaria. These are not equivalent experiences.

Safety context

Misidentification risk

The Amanita genus contains some of the world's most toxic species — including Amanita phalloides (death cap) and Amanita ocreata (destroying angel), which are responsible for the majority of fatal mushroom poisonings globally. Wild mushroom foraging for any purpose requires expert knowledge that goes significantly beyond visual pattern recognition. This guide does not and cannot provide identification guidance.

Wild mushroom foraging carries serious risk of fatal poisoning. No visual guide — including images of Amanita muscaria — should be used for identification of wild fungi.

Legal context

Legal context

Psilocybin and psilocin are controlled substances in most jurisdictions. Amanita muscaria's legal status varies by country and product type. Legal context for both is educational information only — not legal advice.

Verify current legal status in your jurisdiction through official government sources. Legal context on SubsAtlas is educational only.

Related profiles

Substance profiles relevant to this guide. For educational context and risk awareness.

Related comparisons

Structured educational comparisons relevant to this guide.

Related safety topics

Safety topics with relevant risk and interaction context for this guide.

Trust Center context

Relevant sections of the Trust Center that explain how SubsAtlas works.

Related guides

Other educational guides with related context.

← All guidesExplore the AtlasTrust Center

Educational context only. Not medical advice, legal advice, dosing guidance, sourcing guidance or a use guide. Effects, risks and legal status vary by individual, product and jurisdiction.